i&i Biotech Fund

Antiverse is an innovative antibody discovery company that aims to accelerate drug development through its advanced platform. By integrating structural biology, machine learning, and medicine, Antiverse provides solutions to predict antibody-antigen binding and identify potential antibody drug candidates for challenging targets. The company employs machine learning and cell-free protein synthesis to enhance the prediction of antibody affinity for specific antigen targets, allowing pharmaceutical companies and contract research organizations to expedite the antibody hit discovery process. Antiverse is committed to transforming drug development and improving patient outcomes.

Captain T Cell is a start-up focused on developing T cell-based immunotherapies aimed at treating cancer patients, particularly for solid tumors that are inadequately addressed by current therapies. The company specializes in identifying novel, high-efficiency T cell receptors (TCRs) to enhance the efficacy of its immunotherapy candidates. Captain T Cell is engaged in chemistry, manufacturing, and controls (CMC) and preclinical development to advance its lead therapies, aiming to offer innovative treatment options for individuals facing challenging cancer diagnoses.

Casinvent Pharma specializes in developing pharmaceutical solutions aimed at treating selected malignancies. The company focuses on creating therapeutic compounds that utilize proprietary selective inhibitors of enzymes from the Casein Kinase 1 (CK1) family. These inhibitors play a crucial role in regulating the migration of leukemia cells into lymphoid organs, thereby assisting healthcare professionals in the treatment of various cancers, including leukemias, lymphomas, and solid tumors. Through its innovative approach, Casinvent Pharma seeks to improve therapeutic outcomes for patients suffering from these serious conditions.

HeartBeat.bio is a privately funded drug discovery company focusing on the development of a high-throughput 3D screening platform for heart failure and cardiomyopathies.

Delta Diagnostics, founded in 2018 as a spin-off from TNO – The Netherlands Organisation for Applied Scientific Research, specializes in photonic biosensor technology. The company leverages patented innovations developed in TNO's Optics department to commercialize rapid, sensitive, and low-cost biosensors and instruments. These advanced biosensors utilize integrated photonics and optical chips containing waveguides that facilitate the transportation of light across multiple sensors. This technology enables real-time, label-free monitoring of biomarkers, allowing for accurate concentration measurements within minutes. Delta Diagnostics aims to enhance research in life sciences and facilitate the development of novel diagnostics through its innovative biosensing solutions.

Sophomer specializes in the development of synthetic polymers that serve as alternatives to bovine serum albumin in immunological tests. By integrating immunoassays with polymer chemistry, the company offers innovative solutions for immunochemical assays. Its technology aims to improve the reliability and effectiveness of these tests, providing researchers and laboratories with a more consistent and ethical option for their immunological applications.

Enzyre is a developer of innovative diagnostic technology aimed at enhancing patient care while controlling healthcare costs. The company has created a point-of-care diagnostic device that specializes in blood coagulation testing, capable of measuring up to twelve reactions using a small volume of blood. This technology allows patients to perform tests in various settings, including at home, while traveling, or in critical care environments, eliminating the need for laboratory infrastructure. By bringing laboratory capabilities directly to the patient, Enzyre seeks to improve the quality of life for individuals requiring regular monitoring of their health.

Nanoligent is a biotechnology company that originated as a spin-off from the Universitat Autònoma de Barcelona and the Institut de Recerca de l'Hospital de la Santa Creu I Sant Pau. The company focuses on drug design and the development of targeted therapeutic biologics, particularly in the field of anti-cancer treatments for various types of metastatic cancer. Utilizing advanced protein engineering and nanobiotechnology, Nanoligent creates self-assembling protein nanoparticles that selectively target and kill metastatic cells. This innovative approach aims to improve patient outcomes by providing treatments that are more effective and have fewer adverse effects compared to traditional drugs, ultimately enhancing the quality of life for patients battling cancer.

Casinvent Pharma specializes in developing pharmaceutical solutions aimed at treating selected malignancies. The company focuses on creating therapeutic compounds that utilize proprietary selective inhibitors of enzymes from the Casein Kinase 1 (CK1) family. These inhibitors play a crucial role in regulating the migration of leukemia cells into lymphoid organs, thereby assisting healthcare professionals in the treatment of various cancers, including leukemias, lymphomas, and solid tumors. Through its innovative approach, Casinvent Pharma seeks to improve therapeutic outcomes for patients suffering from these serious conditions.

Sampling Human specializes in developing advanced technologies for genetic analysis, focusing on complex single-cell and spatial omic data. The company aims to create compute-driven products that facilitate the measurement and analysis of this data at an industrial scale. Through its innovative solutions, Sampling Human supports various applications in pre-symptomatic screening, personalized medicine, drug discovery, and basic science. This approach enables healthcare professionals to effectively translate extensive datasets into practical applications in diagnostics and bioengineering, ultimately enhancing the capabilities of physicians in addressing complex medical challenges.